Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 6/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SNCA | P37840 | 1/20 | 0.54 |
| ▸ | RHOC | P08134 | 1/20 | 0.52 |
| ▸ | RHOA | P61586 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678064 | 0.91 | PTGS1 (0.77) | PTGS1HDAC3HDAC8HDAC6LMNA | |
| SCHEMBL677476 | 0.86 | MEN1 (0.67) | PTGS1LMNAMEN1POLBPKM | |
| SCHEMBL683803 | 0.86 | PTGS1 (0.68) | PTGS1HDAC3HDAC8HDAC6LMNA | |
| SCHEMBL3246188 | 0.83 | P2RX1 (0.65) | HDAC3HDAC8HDAC6RHOCRHOA | |
| SCHEMBL30554615 | 0.83 | P2RX1 (0.65) | HDAC3HDAC8HDAC6RHOCRHOA | |
| SCHEMBL4421974 | 0.83 | CSF1R (0.52) | PTGS1HDAC3HDAC8HDAC6MEN1 | |
| SCHEMBL20578113 | 0.82 | KDR (0.49) | PTGS1HDAC3HDAC8HDAC6 | |
| SCHEMBL678654 | 0.82 | PTGS1 (1.00) | PTGS1HDAC3HDAC8HDAC6LMNA | |
| SCHEMBL3454009 | 0.81 | PTGS1 (1.00) | PTGS1LMNAMEN1POLBKMT2A | |
| SCHEMBL23985155 | 0.80 | KCNK3 (0.58) | PTGS1LMNAMEN1KMT2ARHOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | claimed |
| JP-2011526912-A | — | — | 2011-10-20 | — | — | JP | claimed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | claimed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | claimed |
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| CN-101952287-A | Kinases inhibitor and application thereof | MERCK SERONO SA | 2011-01-19 | — | — | CN | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | AURKA, AURKC, AURKB | PTGS1 2887/4885HDAC3 1739/4885HDAC8 449/4885 |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | PTGS1 3076/4885HDAC3 1930/4885HDAC8 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.